In a study of patients with T1 glottic squamous cell carcinomas, a group who received transoral microlaryngeal surgery alone had a higher risk for recurrence than a group who received radiotherapy alone, while 5-year overall survival rates remained similar between the two groups. Patients with T1b tumors had lower survival rates and higher rates of laryngectomy than those with T1a tumors.
“The results indicated a significant difference in 5‐year overall survival in favor of T1a vs T1b tumors and that microlaryngeal surgery should be used with caution in patients who have T1b cancer,” the authors wrote.
The study was led by Hedda Haugen Cange, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden. It was published online on June 26, 2025, in Cancer.
The study was limited by its retrospective, observational design. Data were missing on factors like voice quality, quality of life, and comorbidities, which limited comprehensive assessment. Additionally, the small sample size for T1b tumors reduced the study’s statistical power.
The study was funded by Laryngfonden. One author reported serving on a Merck Sharp and Dohme End Point Review Committee outside the submitted work.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.